Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Oncogene ; 20(37): 5100-10, 2001 Aug 23.
Article in English | MEDLINE | ID: mdl-11526498

ABSTRACT

The ATM protein kinase regulates the cell's response to DNA damage by regulating cell cycle checkpoints and DNA repair. ATM phosphorylates several proteins involved in the DNA-damage response, including p53. We have examined the mechanism by which ATM regulates p53's transcriptional activity. Here, we demonstrate that reintroduction of ATM into AT cells restores the activation of p53 by the radio-mimetic agent bleomycin. Further, p53 activation is lost when a kinase inactive ATM is used, or if the N-terminal of ATM is deleted. In addition, AT cells stably expressing ATM showed decreased sensitivity to Ionizing Radiation-induced cell killing, whereas cells expressing kinase inactive ATM or N-terminally deleted ATM were indistinguishable from AT cells. Finally, single point-mutations of serines 15, 20, 33 or 37 did not individually block the ATM-dependent activation of p53 transcriptional activity by bleomycin. However, double mutations of either serines 15 and 20 or serines 33 and 37 blocked the ability of ATM to activate p53. Our results indicate that the N-terminal of ATM and ATM's kinase activity are required for activation of p53's transcriptional activity and restoration of normal sensitivity to DNA damage. In addition, activation of p53 by ATM requires multiple serine residues in p53's transactivation domain.


Subject(s)
Cell Cycle Proteins , Genes, p53/genetics , Protein Serine-Threonine Kinases/chemistry , Serine/chemistry , Transcription, Genetic , Tumor Suppressor Protein p53/chemistry , Antimetabolites, Antineoplastic/pharmacology , Ataxia Telangiectasia Mutated Proteins , Bleomycin/pharmacology , Blotting, Western , Cell Line , DNA Damage , Dose-Response Relationship, Drug , Dose-Response Relationship, Radiation , Enzyme Activation , Gene Deletion , Humans , Mutagenesis, Site-Directed , Mutation , Phosphorylation , Precipitin Tests , Protein Structure, Tertiary , Transcriptional Activation
2.
BMC Cell Biol ; 2: 12, 2001.
Article in English | MEDLINE | ID: mdl-11483158

ABSTRACT

BACKGROUND: The p53 protein is activated by genotoxic stress, oncogene expression and during senescence, p53 transcriptionally activates genes involved in growth arrest and apoptosis. p53 activation is regulated by post-translational modification, including phosphorylation of the N-terminal transactivation domain. Here, we have examined how Glycogen Synthase Kinase (GSK3), a protein kinase involved in tumorigenesis, differentiation and apoptosis, phosphorylates and regulates p53. RESULTS: The 2 isoforms of GSK3, GSK3alpha and GSK3beta, phosphorylate the sequence Ser-X-X-X-Ser(P) when the C-terminal serine residue is already phosphorylated. Several p53 kinases were examined for their ability to create GSK3 phosphorylation sites on the p53 protein. Our results demonstrate that phosphorylation of serine 37 of p53 by DNA-PK creates a site for GSK3beta phosphorylation at serine 33 in vitro. GSK3alpha did not phosphorylate p53 under any condition. GSK3beta increased the transcriptional activity of the p53 protein in vivo. Mutation of either serine 33 or serine 37 of p53 to alanine blocked the ability of GSK3beta to regulate p53 transcriptional activity. GSK3beta is therefore able to regulate p53 function in vivo. p53's transcriptional activity is commonly increased by DNA damage. However, GSK3beta kinase activity was inhibited in response to DNA damage, suggesting that GSK3beta regulation of p53 is not involved in the p53-DNA damage response. CONCLUSIONS: GSK3beta can regulate p53's transcriptional activity by phosphorylating serine 33. However, GSK3beta does not appear to be part of the p53-DNA damage response pathway. Instead, GSK3beta may provide the link between p53 and non-DNA damage mechanisms for p53 activation.


Subject(s)
Glycogen Synthase Kinase 3/metabolism , Serine/metabolism , Trans-Activators/chemistry , Trans-Activators/metabolism , Tumor Suppressor Protein p53/chemistry , Tumor Suppressor Protein p53/metabolism , Cell Line , Glycogen Synthase Kinase 3 beta , Humans , Phosphorylation/radiation effects , Transcriptional Activation
3.
Curr Biol ; 9(19): 1135-8, 1999 Oct 07.
Article in English | MEDLINE | ID: mdl-10531013

ABSTRACT

The basis of many anti-cancer therapies is the use of genotoxic agents that damage DNA and thus kill dividing cells. Agents that cause cells to override the DNA-damage checkpoint are predicted to sensitize cells to killing by genotoxic agents. They have therefore been sought as adjuncts in radiation therapy and chemotherapy. One such compound, caffeine, uncouples cell-cycle progression from the replication and repair of DNA [1] [2]. Caffeine therefore servers as a model compound in establishing the principle that agents that override DNA-damage checkpoints can be used to sensitize cells to the killing effects of genotoxic drugs [3]. But despite more than 20 years of use, the molecular mechanisms by which caffeine affects the cell cycle and checkpoint responses have not been identified. We investigated the effects of caffeine on the G2/M DNA-damage checkpoint in human cells. We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro. Inhibition of ATM provides a molecular explanation of the attenuation of DNA-damage checkpoint responses and for the increased radiosensitivity of caffeine-treated cells [6] [7] [8].


Subject(s)
Caffeine/pharmacology , Carrier Proteins , Cell Cycle/drug effects , Protein Serine-Threonine Kinases/antagonists & inhibitors , Protein Serine-Threonine Kinases/metabolism , Adaptor Proteins, Signal Transducing , Androstadienes/pharmacology , Ataxia Telangiectasia Mutated Proteins , Cell Cycle Proteins , Cell Line , Checkpoint Kinase 2 , DNA Damage , DNA-Binding Proteins , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , HeLa Cells , Humans , Phosphoproteins/metabolism , Phosphorylation , Precipitin Tests , Protein Kinases/metabolism , Protein Serine-Threonine Kinases/drug effects , Time Factors , Tumor Suppressor Proteins , Wortmannin
SELECTION OF CITATIONS
SEARCH DETAIL
...